Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk, a Danish healthcare company and world leader in diabetes care, in 1986 and has been part of the pharmaceutical group since then.

On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of products such as recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical and personal care industries.

Novo Nordisk Pharmatech A/S is a leading global supplier of high-quality ingredients for the biopharmaceutical and pharmaceutical industries. The company has attracted an extensive roster of leading pharmaceutical companies through unsurpassed product quality, manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy.

Our history started in 1949:

1949 – The Ferrosan Fine Chemicals factory is established, part of the Ferrosan Group

1986 – Novo Industries acquire the Ferrosan Group

1989 – Merger of Novo Industries and Nordisk Gentofte to become Novo Nordisk A/S

1990 – Novo Nordisk initiates the sale of the Ferrosan Group but keeps the site in Koege. Ferrosan Fine Chemicals becomes a limited company and a fully owned subsidiary of Novo Nordisk A/S

1991 – First GMP approval by the Danish Medicines Agency for the manufacture of Quaternary Ammonium Compounds (Quats)

1992 – The company name is changed to FeF Chemicals A/S and was ISO 9002 certified

1995 – Novo Nordisk sells the remaining of the Ferrosan Group

2001/2005 – Certificate of Suitability (CEP) for Benzalkonium Chloride and Cetrimide products

2002 – ISO 9001:2000 & ISO 14001:1996 certified

2004 – Fully integrated in the Product Supply/Devices & Sourcing business unit of Novo Nordisk

2005 – ISO 14001:2004 certified

2009 – OHSAS 18001 certified

2010 – Fully integrated in the Product Supply business unit of Novo Nordisk A/S, Denmark – a 12 billion US$ diabetes Care and Biopharmaceuticals company

2011 – Acquiring sales and distribution of Insulin Human for cell growth media

2012 – Full acquisition of Insulin Human business and building of classified room facility

2015 – FeF Chemicals A/S changes name to Novo Nordisk Pharmatech A/S

2016 – FDA inspected

2018 – ISO 9001:2015 certified

2018 – ISO 14001:2015 certified

2019 – Establishment of Singapore Branch Office

2020 – ISO 45001 certified

2021 – Establishment of Branch Office in Boston, USA

2022 – Strategic partnership with Novozymes

2022 – Affinity Resins to Novo Nordisk

2023 – Enterokinase and 2G ALP to Novo Nordisk

Click here to read more about us.